替尼泊甙与依托泊甙治疗晚期非小细胞肺癌的对比研究

CONTROLLED STUDY TENIPOSIDE AND ETOPOSIDE FOR ADVANCED NSCLC

目的比较替尼泊甙（ＶＭ－１６）与依托泊甙（ＶＰ－１６）对晚期非小细胞肺癌的疗效。方法晚期非小细胞肺癌６１例，随机分为Ａ、Ｂ两组，Ａ组应用顺铂（ＤＤＰ）＋ＶＰ－１６方案化疗，Ｂ组应用ＤＤＰ＋ＶＭ－２６方案化疗，２～３周期化疗后评价疗效和不良作用。结果Ａ组有效率为３７．５％（１２／３２），Ｂ组有效率为３３．３％（７／２１），两组无显著差异。Ａ组与Ｂ组Ⅲ～Ⅳ级骨髓毒性发生率分别为２８．１％和２３．８％，Ⅱ～Ⅲ级胃肠道毒性发生率分别为３１．３％和２３．８％。结论ＶＭ－２６治疗晚期非小细胞肺癌的有效率与ＶＰ－１６相似，而不良反应发生率低。

PURPOSE To compare the anticancer results of VM 26 with VP 16 in advanced non small cell lung cancer. METHODS 61 histologically confirmed NSCLC patients were randomized into two groups after hospitalization. One group was treated wth DDP+VP 16,the other with DDP+VM 26, 21 days per cycle. Patients who completed at least 2 cycles were evaluated. RESULTS 53 patients were evaluated. The response rates for VP 16 and VM 26 groups 37 5% (12/32) and 33 3% (7/21) respectively. There was no significant difference ( P >0 05).The side effects of the two groups were mainly hematologic and gastrointestinal toxicities. CONCLUSIONS VM 26 is an effective agent for NSCLC,and its toxicities are moderate.